

Hyloris

9 oktober 2023

De Belegger On Tour



Disclaimer

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, "presentation" means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person's organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.


This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company.

De uitdaging van de biotech-belegger

> 20,000
geneesmiddelen
in ontwikkeling



43
goedgekeurd
/jaar

Grote onervulde medische behoeften

Wij doen het anders

Bestaande medicijnen heruitvinden



Verbeteringen voor patienten, dokters & ziekteverzekeringen

Onopgeloste medische uitdagingen aanpakken

Pijlpijn uitbreiden



Input van wetenschappers, dokters



Gekende moleculen



Duidelijk regulatorisch pad



Patentbescherming



Meerwaarde voor gezondheidszorg



Grote opportuniteiten



Vlotte commerciële uitrol



Hoge return



Groot potentieel

Ambitie om marktleider te worden in dit segment

Cardiovasculaire portfolio 7 (kandidaat-)producten

Grootste therapeutisch domein



- 1 product gelanceerd in the VS (Sotalol IV)
- 6 producten in ontwikkeling
 - Hartfalen, Acut Coronair Syndroom, voorkamerfibrilatie, ...
 - Meerdere (finale) klinische studies uitvoeren in 2023/2024
- Focus op **Amerikaanse markt**
- Ziekenhuisproducten voor **beperkt aantal artsen**
 - ➔ Relatief **kleine verkooptploeg** nodig

Meerdere indieningen + goedkeuringen (VS) verwacht in 2024-2026

Andere toegevoegde waarde portfolio (9 producten)

Een selectie

Alenura™



→ **Pijnverzachting** voor miljoenen patiënten wereldwijd met **acute blaaspijn**

Miconazole-Domiphen Bromide



→ Lokale behandeling voor vrouwen met **hardnekkige vaginale schimmels**

Plecoïd Agents™



→ **Uitkomst chemotherapie verbeteren** voor patiënten met AML (Leukemie)/SCLC

HY-083



→ **First-in-class geneesmiddel** voor idiopathische rhinitis

Tranexamic Acid mondspoeling



→ **Lokale bloedingen bij tandzorg** behandelen

Maxigesic IV®



→ **Injecteerbare non-opioïde, krachtige post-operatieve pijnstiller**

Wereldwijde opportuniteiten in verschillende therapeutische domeinen

Maxigesic IV

Wapen in de strijd tegen opioïden crisis in de VS

9%


Raakt verslaafd aan opioïden na post-operatief gebruik (1)

\$11
miljard

Extra kosten voor Amerikaanse gezondheidszorg (2)

45

Doden per dag na overdosis met voorschrijfmedicatie (3)



Drastische vermindering in opioïdenconsumptie

Potentiële goedkeuring in de VS rond 17 oktober 2023

(1) [Chronic Opioid Usage in Surgical Patients in a Large Academic Center - PubMed \(nih.gov\)](#)

(2) [Premier | Opioid Overdoses Costing U.S. Hospitals an Estimated \\$11... \(premierinc.com\)](#)

(3) <https://www.cdc.gov/opioids/data/index.html>

Hyloris: Evolutie sinds IPO



Adviezen voor ons aandeel

Bank	Analist	Rating
Berenberg	Beatrice Allen	Buy
KBC Securities	Jacob Mekhael	Buy
Kempen	Suzanne van Voorthuizen	Buy
Degroof Petercam	David Seynnaeve	Buy
Kepler Cheuvreux	Christophe Dombu	Buy

Omzet & ander inkomen (H1 2023): **€2,4 mio (+95%)**

Cashpositie (H1 2023): **+€39 million**

Hyloris: een transformatie in wording

Brede portfolio, gedreven door potentieel

≤ 7 jaar tot commercialisatie

≤ €7 miljoen gemiddelde kost

Lager risico met gekende molecules

Innovatie & patentbescherming

30 (kandidaat-)producten verwacht tegen 2025

Commerciële uitrol

2 early-stage producten leveren vandaag al royalties

Onopgeloste medische uitdagingen

Relatief klein commercieel team in de VS voor
cardiovasculaire range

Out-licensing naar lokale, sterke distributeurs

Ambitie om marktleider te worden in dit segment

Hyloris

A person wearing a green lab coat, a white hairnet, and a white face mask is working in a laboratory. They are focused on a piece of equipment that includes a clear cylindrical container and various tubes and wires. The background is slightly blurred, showing a typical laboratory setting with bright lighting.

Belegger on Tour
9 oktober 2023